Skip to content

Events & Presentations

UPCOMING EVENTS

There are currently no events to display. Please click here to be notified of all upcoming events.

PRESENTATIONS

Date Documents

ARCHIVED EVENTS

Date Event Details
Summary Toggle September 6, 2018 9:00 AM EDT
2018 Citi Biotech Conference Panel: “Landscape in Immuno-Oncology and Bi-Specific Antibodies” Panel
Additional Information

Panel Participants Include:

CytomX Therapeutics, Inc. - Sean McCarthy, D. Phil. – President and Chief Executive Officer 
Macrogenics Scott Koenig – President & CEO 
Merus (MRUS)Ton Logtenberg, Ph.D, – Chief Executive Officer
Mirati Therapeutics, Inc.Charles Baum – President & CEO
Zymeworks Inc.Ali Tehrani – Chief Executive Officer 

Summary Toggle September 5, 2018 3:15 PM EDT
2018 Citi Biotech Conference Panel: “Targeted Therapies Oncology - Aiming for the Bull's Eye”
Additional Information
Panel Participants Include:
   
Arcus Biosciences, Inc. – Terry Rosen – Co-Founder & CEO 
Epizyme, Inc. - Robert Bazemore – President & CEO
Deciphera Pharmaceuticals Inc.Michael Taylor – President & CEO 
Halozyme Therapeutics, Inc.Helen Torley – President & CEO 
Mirati Therapeutics, Inc.Charles Baum – President & CEO 
Summary Toggle June 8, 2018 8:30 AM EDT
Jefferies 2018 Global Healthcare Conference

ABSTRACTS AND POSTERS

Date Event Details
Summary Toggle December 6, 2016
Summary Toggle December 6, 2016
Summary Toggle December 6, 2016
Summary Toggle December 6, 2016
Summary Toggle October 8, 2016
Summary Toggle June 5, 2016
A First-in-Human Phase 1 Study of Receptor Tyrosine Kinase (RTK) Inhibitor anced Solid Tumors

Supporting Materials

Summary Toggle June 4, 2016
Evaluation of a spray-dried dispersion (SDD) formulation of MGCD265, a receptor tyrosine kinase (RTK) inhibitor, in a phase 1 study of patients (pts) with advanced solid tumors

Supporting Materials

Summary Toggle June 4, 2016
Phase 2, Parallel-Arm Study of Receptor Tyrosine Kinase(RTK) Inhibitor MGCD265 in Patients (pts) with Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with Activating Genetic Alterations in Mesenchymal-Epithelial Transition Factor (MET)

Supporting Materials

Summary Toggle April 19, 2016
The class I HDAC inhibitor, mocetinostat, induces expression of PD-L1 and tumor antigen presentation machinery and modifies tumor immune cellular subsets providing a rationale for immune checkpoint inhibitor combinations AACR 2016
Summary Toggle April 18, 2016
Evaluation of the mechanism of MET-dependent cellular transformation and potent cytoreductive activity of MGCD265 in novel MET exon 14 mutation positive cancer models AACR 2016

Supporting Materials

Summary Toggle April 16, 2016
Summary Toggle September 27, 2015
A First-in-Human Phase 1/1b Study of Receptor Tyrosine Kinase (RTK) Inhibitor, MGCD516, in Patients with Advanced Solid Tumors 2015 European Cancer Congress

Supporting Materials

Summary Toggle September 9, 2015
Evaluation of the MET/Axl Receptor Tyrosine Kinase (RTK) Inhibitor MGCD265 in a Patient with Metastatic Non-Small Cell Lung Cancer (NSCLC) Harboring Axl Amplification World Conference on Lung Cancer 2015

Supporting Materials

Summary Toggle September 8, 2015
In Vitro and In Vivo Evaluation of the Kinase Inhibitor, MGCD516, in TRK and RET Fusion Cancer cells World Conference on Lung Cancer 2015

Supporting Materials

Summary Toggle May 30, 2015
A First-in-Human Phase 1/1b Study of Receptor Tyrosine Kinase (RTK) Inhibitor MGCD516 in Patients with Advanced Solid Tumors ASCO 2015

Supporting Materials

Summary Toggle May 30, 2015
Phase 1 Study of Receptor Tyrosine Kinase (RTK) Inhibitor, MGCD265, in Patients (pts) with Advanced Solid Tumors ASCO 2015
Summary Toggle May 29, 2015
A Phase 2 Study of the Histone Deacetylase (HDAC) Inhibitor Mocetinostat in Patients with Urothelial Carcinoma (UC) and Inactivating Alterations of Acetyltransferase Genes ASCO 2015

Supporting Materials